It’s no secret that cannabinoids offer a multitude of skin care benefits as witnessed with the mainstream boom of cannabidiol (CBD) and tetrahydrocannabinol (THC) in formulations. However, more recent research is showing that cannabigerol (CBG) has the potential to treat some of the most common skin conditions as a natural anti-inflammatory, antimicrobial, and antioxidant to possibly alleviate psoriasis, eczema, acne, and even the ravages of aging.

Roy Lipski has led technology companies based on cutting-edge science for 25 years. Prior to founding Creo, he worked as CEO and co-founder of Oxford Catalysts plc (later Velocys plc) for nearly 10 years, during which time he took the company through an IPO, subsequent merger, and financings totaling over $215 million. Previously, Lipski was entrepreneur-in-residence at IP Group plc, the University VC and technology transfer specialist, where he was responsible for creating new businesses and opportunities. For eight years prior, Lipski was also the managing director and founder at Infonic Ltd, an artificial intelligence software business focused on sentiment analysis in language that was acquired by Corpora plc, a publicly listed company. Lipski began his career at Goldman Sachs in London. He holds a Bachelor of Arts Honors degree in natural sciences from Trinity College, University of Cambridge, where he was awarded a Trinity College junior scholarship.